

Table S1: Baseline patient characteristics and treatment received

		N (%)
Age	Mean of median age (range)	64.3 (63 – 66) [‡]
Sex	Male	2963 (67.7)
	Female	1415 (32.3)
Smoking status	Smoker (current or previous)	3778 (86.3)
	Never smoker	589 (13.5)
Performance status	0	1518 (34.7)
	1	2662 (60.8)
Histology	Non-squamous	2942 (67.2)
	Squamous	1430 (32.7)
Systemic therapy	Cisplatin	203 (7.5)
	Carboplatin	2498 (92.5)
	Pemetrexed	817 (30.2) [#]
	Taxane (paclitaxel, nab-paclitaxel)	1407 (52.1) [~]
	Gemcitabine	77 (2.9) ^{\$}
	Bevacizumab	400 (14.8)
Ventana SP142	PD-L1 Negative	539 (14.4)
	PD-L1 Low	546 (14.5)
	PD-L1 High	268 (7.1)
Dako 22C3	PD-L1 Negative	162 (4.3)
	PD-L1 Low	499 (13.3)
	PD-L1 High	594 (15.8)
PharmDx 28-8	PD-L1 Negative	265 (7.1)

	PD-L1 Low	365 (9.7)
	PD-L1 High	316 (8.4)

‡Median age not reported in IMPOWER110 trial

Use of cisplatin reported in CHECKMATE026, KEYNOTE024, CHECKMATE9LA and KEYNOTE189 trials

Use of carboplatin reported in IMPOWER130, IMPOWER131, KEYNOTE024, KEYNOTE042, KEYNOTE 189, KEYNOTE407, CHECKMATE9LA and CHECKMATE026 trials

#Use of pemetrexed reported in CHECKMATE026, CHECKMATE9LA, KEYNOTE024, KEYNOTE042 and KEYNOTE189 trials

~Use of paclitaxel or nab-paclitaxel reported in IMPOWER130, IMPOWER131, KEYNOTE024, KEYNOTE042, KEYNOTE407, CHECKMATE9LA and CHECKMATE026 trials

\$Use of gemcitabine reported in KEYNOTE024 and CHECKMATE026 trials